Although targeted inhibitors of mutant IDH have shown promise in IDH mutant acute leukaemia patients, no benefits have been obtained for patients affected by gliomas, despite the reduction in D2-HG after treatment with inhibitors. This evidence concerns the gene IDH1 and central nervous system cancer.